Our Science

Our Science : Drug Discovery Platforms : High Throughput Screening

Benefits of scale and format variety enable us to rapidly differentiate false-positives from quality hits.

Over the course of a year, FORMA demonstrates screening productivity on the order of 35 million wells against 30 targets using high-throughput screening (HTS) robots. The use of seven to eight standard biochemical assay formats has been typical for a screening campaign, including an additional proprietary cell-based screening technology, MAPPIT (Mammalian Protein-Protein Interaction Trap), when examining protein-protein interaction targets. Benefits of scale and format variety enable us to rapidly differentiate false-positives from quality hits.

CELL-BASED SCREENING

Since dynamic interactions among proteins essentially govern all cell processes, insights into disease-relevant biological and pharmacological phenomena can be derived from protein interaction data generated within an intracellular context. In concert with biochemical HTS, we apply versatile cell-based screening platforms to screen discrete targets for active compounds under the most relevant conditions.

 


Our MAPPIT screen is a proprietary, cell-based assay ideally suited for interrogating protein-protein interactions and assisting target identification. MAPPIT uses a mammalian two-hybrid technique based on reconstitution of cytokine receptor signal transduction mechanisms. Specifically, bait and prey proteins are linked to signaling-deficient receptor chimeras. Interactions of bait and prey proteins restore functional JAK-STAT signaling in response to an extracellular receptor ligand, such as erythropoietin, leading to the transcription of a reporter gene that is under the control of a STAT-responsive promoter.